Sara1

[Sara’s Story #1] “Exams will be starting soon, announcing the end of another term. But I can only think about my MS—will that announce the end of my education, my hopes of studying medicine or my chance of becoming a pediatrician?

I had my life planned step by step. Now, every next step could signal a relapse: the tingling, the dizziness, the exhaustion. How badly will disability affect me? Will I eventually need help walking? And honestly, a child will be afraid to see me struggling into the exam room using arm crutches.”

As a medical student—one who walks to class every day with dreams of beginning a promising career—Sara’s future is in your care. As a neurologist, what do you suppose Sara stands to lose if she continues to relapse on her current therapy?

But Sara’s story need not go this way. In fact, Sara has a lot to gain if you recommend a higher-efficacy treatment like PRODUCT X—Earlier in the course of disease.

Only PRODUCT X has been proven to deliver near-complete suppression of subclinical (MRI) activity with superior clinical outcomes versus high-dose IFN β-1a in two identical 2-year trials. This superior efficacy is complemented a favourable safety profile that allows you to intervene earlier in the course of disease—so you can halt further disease progression.

For you, it comes down to making the decision to switch Sara onto PRODUCT X. For Sara, there is so much to be gained: The future for which she has always planned.

At any sign of disease activity, start PRODUCT X now.